2014 News Releases

2014 News Releases

Pacira Pharmaceuticals Inc. Announces Changes to EXPAREL® Label
12/12/14
Pacira Pharmaceuticals, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference
11/25/14
Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2014 Global London Healthcare Conference
11/11/14
Pacira Pharmaceuticals Inc. Announces New Data on the Use of EXPAREL to Treat Postsurgical Pain Following Total Knee Arthroplasty
11/06/14
Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue of $50.2 Million and Third Quarter 2014 Results
10/30/14
New Study Correlates Use of EXPAREL for Postsurgical Pain Management with Significant Reductions in Opioid Related Adverse Events
10/27/14
Pacira Pharmaceuticals Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call
10/15/14
Pacira Pharmaceuticals, Inc. Announces Additional Data Supporting Safety of EXPAREL® in Peripheral Nerve Block
10/13/14
Pacira Pharmaceuticals, Inc. Announces Receipt of FDA Warning Letter
09/25/14
Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference
08/05/14
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2014 Results: EXPAREL Revenue up 31% Over First Quarter
07/31/14
Pacira Pharmaceuticals Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call
07/17/14
Pacira Pharmaceuticals, Inc. Announces Publication of Pooled Results from IMPROVE Studies Evaluating Health Economic Benefits of EXPAREL®
06/26/14
Pacira Pharmaceuticals, Inc. to Present at June Investor Conferences
05/27/14
Pacira Pharmaceuticals, Inc. Announces sNDA Submission for EXPAREL Nerve Block Indication
05/07/14
Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
05/05/14
Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenue of $34.4 Million and First Quarter 2014 Results
05/01/14
Pacira Pharmaceuticals Announces Timing for First Quarter 2014 Financial Results Webcast and Conference Call
04/17/14
Pacira Pharmaceuticals Announces Grants of Inducement Stock Options Under NASDAQ Listing Rule 5635(c)(4)
04/15/14
Pacira Pharmaceuticals Announces Pricing of Public Offering of Common Stock
04/08/14
Pacira Pharmaceuticals Announces Proposed Public Offering of Common Stock
04/07/14
Pacira Pharmaceuticals Enters into Strategic Co-Production Partnership with Patheon to Create Additional EXPAREL Manufacturing Capacity
04/07/14
EXPAREL Use in Femoral Nerve Block for Total Knee Arthroplasty Further Supported by Additional Data from Phase 3 Pivotal Study, sNDA Submission Planned for Second Quarter 2014
04/04/14
Pacira Pharmaceuticals, Inc. Announces FDA Approval of Additional Manufacturing Suite for EXPAREL
03/31/14
Two New Studies Support Use of EXPAREL for Postsurgical Pain Management Following Total Joint Replacement
03/14/14
Pacira Pharmaceuticals Inc. Appoints Industry Expert Yvonne Greenstreet to its Board of Directors
03/06/14
Pacira Pharmaceuticals Announces EXPAREL® Data Presentations at 2014 Annual Meeting of the American Academy of Orthopedic Surgeons
03/05/14
Pacira Pharmaceuticals, Inc. Announces EXPAREL Phase 3 Clinical Trial in Femoral Nerve Block Meets Primary Efficacy Endpoint
02/27/14
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
02/26/14
Pacira Pharmaceuticals, Inc. Webcast Replay of 2013 Financial Results Conference Call
02/25/14
Pacira Pharmaceuticals, Inc. Reports 2013 Financial Results: Fourth Quarter EXPAREL Revenues Increase 53 Percent Over Third Quarter
02/25/14
Pacira Pharmaceuticals, Inc. Announces Timing for 2013 Financial Results Webcast and Conference Call
02/11/14
Data Update Supports Infiltration with EXPAREL® into the Transversus Abdominis Plane for Postsurgical Pain Management
01/29/14
Phase 4 IMPROVE Publication Finds EXPAREL®- Based Multimodal Analgesia Reduces Opioid Use, Adverse Events and Hospital Stay Following Laparoscopic Surgery
01/07/14